A phase II trial of lapatinib and pazopanib for patients with recurrent glioblastoma multiforme (GBM)

被引：0

作者：

Reardon, David ^{[1
]}

Groves, Morris ^{[2
]}

Wen, Patrick ^{[3
]}

Nabors, Louis ^{[4
]}

Mikkelsen, Tom ^{[5
]}

Rosenfeld, Steve ^{[6
]}

Harris, Dean ^{[7
]}

DeMarini, Douglas

Suttle, Ben ^{[8
]}

Arumugham, Thangam ^{[8
]}

Hodge, Jeffrey ^{[8
]}

Lager, Joanne ^{[8
]}

机构：

[1] Duke Univ, Durham, NC USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Dana Farber Canc Inst, Boston, MA USA

[4] Univ Alabama, Birmingham, AL USA

[5] Henry Ford Hlth Syst, Detroit, MI USA

[6] Columbia Univ, New York, NY USA

[7] Royal Marsden Hosp, Surrey, England

[8] GlaxoSmithKline Inc, Durham, NC USA

来源：

NEURO-ONCOLOGY | 2007年 / 9卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：516 / 516

页数：1

共 50 条

[21] N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM)
Galanis, E.
Jaeckle, K. A.
Maurer, M. J.
Reid, J. M.
Ames, M. M.
Giannini, C.
Hardwick, J. S.
Moore, D. F., Jr.
Zwiebel, J. A.
Buckner, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[22] A Prospective 4I Radiotherapy Clinical Trial in Recurrent Glioblastoma Multiforme (GBM) Patients
Yu, V.
Landers, A.
Woods, K.
Nguyen, D.
Cao, M.
Chin, R.
Kaprealian, T.
Sheng, K.
MEDICAL PHYSICS, 2017, 44 (06) : 2999 - 3000
[23] Fotemustine in recurrent or progressive glioblastoma multiforme (GBM)
Savio, G.
Pepe, A.
Laudani, A.
Leonardi, V
Usset, A.
Rondello, G.
Arcuri, C.
Palmisano, V
Alu', M.
Macaluso, M.
Agostara, B.
ANNALS OF ONCOLOGY, 2007, 18 : 80 - 80
[24] Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM)
Krishnan, S
Brown, P
Ballman, K
Fiveash, J
Uhm, J
Giannini, C
Geoffroy, F
Nabors, L
Buckner, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 117S - 117S
[25] Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme
Puduvalli, VK
Giglio, P
Groves, MD
Hess, KR
Jackson, E
Mahankali, S
Gilbert, M
Levin, VA
Conrad, C
Hsu, S
Yung, WKA
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 120S - 120S
[26] Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme
Sathornsumetee, S.
Vredenburgh, J. J.
Rich, J. N.
Desjardins, A.
Quinn, J. A.
Mathe, A. E.
Gururangan, S.
Friedman, A. H.
Friedman, H. S.
Reardon, D. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[27] PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
Reardon, David A.
Sathornsumetee, Sith
Vredenburgh, James J.
Rich, Jeremy N.
Desjardins, Annick
Quinn, Jennifer A.
Mathe, Alyssa
Gururangan, Sridharan
Friedman, Allen H.
Friedman, Henry S.
NEURO-ONCOLOGY, 2009, 11 (02) : 231 - 231
[28] Phase II trial of high dose imatinib in recurrent glioblastoma multiforme (GBM) with platelet derived growth factor receptor (PDGFR) expression
Viola, F. S.
Katz, A.
Arantes, A.
Gaiger, A.
Vasconcellos, C.
Passos, V.
Barrios, C. H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[29] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma
Pipas, JM
Meyer, LP
Rhodes, CH
Cromwell, LD
McDonnell, CE
Kingman, LS
Rigas, JR
Fadul, CE
JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (03) : 301 - 305
[30] A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Raizer, Jeffrey J.
Abrey, Lauren E.
Lassman, Andrew B.
Chang, Susan M.
Lamborn, Kathleen R.
Kuhn, John G.
Yung, W. K. Alfred
Gilbert, Mark R.
Aldape, Kenneth A.
Wen, Patrick Y.
Fine, Howard A.
Mehta, Minesh
DeAngelis, Lisa M.
Lieberman, Frank
Cloughesy, Timothy F.
Robins, H. Ian
Dancey, Janet
Prados, Michael D.
NEURO-ONCOLOGY, 2010, 12 (01) : 95 - 103

← 1 2 3 4 5 →